ADC Therapeutics SA blamed patients’ advanced age on the death imbalance in the phase III Lotis-5 confirmatory trial testing Zynlonta (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Whatever the reason, Wall Street wasn’t pleased and shares (NYSE:ADCT) closed June 4 at $1.32, down 57%, or $1.77. Read More
Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results. Read More
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous system thyroid hormone receptor agonist, or thyromimetic, is moving toward a registrational path and a clinical readout in major depressive disorder. Read More
The U.S. Supreme Court handed Hikma Pharmaceuticals and the entire generic industry a big victory June 4 with its 9-0 opinion ensuring the future of skinny labels and correcting the Federal Circuit’s flawed understanding of infringed inducement. Read More
Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam. Read More
The BioWorld Neurological Diseases Index (BNDI) ended May up 12.29% for the year, outpacing both the Nasdaq Biotechnology Index (up 4.95%) and the Dow Jones Industrial Average (up 6.18%), a reversal from 2025 when the BNDI trailed both broader benchmarks. Read More
The microbiome and a frontline innate antimicrobial sensor, Toll-like receptor 5 (TLR5), play an essential role in the development of idiopathic pulmonary fibrosis (IPF). A scientific collaboration led by researchers at the National Institute of Environmental Health Sciences has revealed how TLR5 protects against fibrosis through its ability to modulate the lung microbiome. Their study also shows that activating TLR5 protects against fibrosis and corrects pulmonary dysbiosis. Read More
New hires and promotions in the biopharma and med-tech industries, including: Celularity, Cocrystal, Corrixr, Cue Biopharma, Defence, Jenavalve, Natera, Neuronetics, Noah, Ovid, Precision, Transverse. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Advanced Nanotherapies, Bluejay, Liminatus, Lixte, Medtronic, Mineralys, Nrx. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Argenx, Cabaletta, JJP, J&J, Kura, Kyverna, Legend, Tenaya, TG, Transcode, Zenas. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abbott, Alnylam, Alpha Tau, Astrazeneca, Axsome, Daiichi, Inceptive, Leica, Minimed, Nanodetection, Oligomerix Tolmar. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Agilent, Coloplast, Cycle, Hopstem, Orthalign, QT, Reach, Royal, Sotio, Terremoto, Waters, Xenix. Read More
